ADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has announced its participation in two major investor conferences this November.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has announced its participation in two major investor conferences this November. The company will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 11:00 a.m. ET, and the Jefferies London Healthcare Conference on November 19, 2024, at 11:00 a.m. GMT. Both presentations will feature CEO Ameet Mallik in fireside chat formats. Live webcasts will be available on the company's investor relations website, with replays accessible for approximately 30 days after each event.
Details
News Market Reaction – ADCT
The recorded move for ADCT in the trading session of this news was +2.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Guggenheim Securities Healthcare Innovation Conference
Date: November 11, 2024
Presentation Time: 11:00 a.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
Jefferies London Healthcare Conference
Date: November 19, 2024
Presentation Time: 11:00 a.m. GMT
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days following each event.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-present-at-november-investor-conferences-302294663.html
SOURCE ADC Therapeutics SA
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.